Clinical Trials Browser

Interventional × Inflammatory Breast Neoplasms × Bevacizumab × Clear all

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase 2 Completed

105 enrolled 17 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00820547 2019-10-22

Beverly1

Phase 2 Completed

100 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT00016549 2017-07-02

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

Phase 2 Completed

21 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00856492 2017-06-27

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Phase 2 Completed

215 enrolled 13 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00957125 2016-09-08

PROMIX

Phase 2 Unknown

151 enrolled

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01426880 2016-02-15

GeparSixto

Phase 2/3 Completed

595 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT01880385 2013-06-19

Beva

Phase 1 Unknown

30 enrolled

Breast

Inflammatory Breast Neoplasms

NCT01641406 2012-07-16

NACprotocol

Phase 2 Unknown

60 enrolled

Breast

Breast Carcinoma In Situ, Carcinoma, Lobular, Inflammatory Breast Neoplasms

NCT01093235 2010-03-25

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer

Phase 3 Unknown

800 enrolled

Breast

Breast Neoplasms, Postoperative Complications, Breast Neoplasms, Male, Inflammatory Breast Neoplasms, Cardiotoxicity